431980-38-0Relevant articles and documents
Synthesis and structure-activity relationship studies of hiv-1 virion infectivity factor (vif) inhibitors that block viral replication
Ali, Akbar,Wang, Jinhua,Nathans, Robin S.,Cao, Hong,Sharova, Natalia,Stevenson, Mario,Rana, Tariq M.
, p. 1217 - 1229 (2012/07/17)
The human immunodeficiency virus1 (HIV-1) virion infectivity factor (Vif) protein, essential for in vivo viral replication, protects the virus from innate antiviral cellular factor apolipoproteinB mRNA-editing, enzyme-catalytic, polypeptide-like3G (APOBEC
SAR and lead optimization of an HIV-1 Vif-APOBEC3G axis inhibitor
Mohammed, Idrees,Parai, Maloy K.,Jiang, Xinpeng,Sharova, Natalia,Singh, Gatikrushna,Stevenson, Mario,Rana, Tariq M.
, p. 465 - 469 (2012/09/22)
We describe structure-activity relationship and optimization studies of RN-18, an HIV-1 Vif-APOBEC3G axis inhibitor. Targeted modifications of RN-18 ring C, ring B, ring A, bridge A-B, and bridge B-C were performed to identify the crucial structural features, which generated new inhibitors with similar (4g and 4i) and improved (5, 8b, and 11) activities. Two potent water-soluble RN-18 analogues, 17 and 19, are also disclosed, and we describe the results of pharmacological studies with compound 19. The findings described here will be useful in the development of more potent Vif inhibitors and in the design of probes to identify the target protein of RN-18 and its analogues.
Composition and synthesis of new reagents for inhibition of HIV replication
-
Page/Page column 26; 27, (2008/06/13)
The present invention provides compounds and compositions for inhibiting Vif and methods for treating viral infection, e.g., HIV infection.